EFTA00506070Set 9
2013-08-2236p3,940w
Reliant Pharmaceuticals -developed tablet formulation (RP-606)
• Ucensed to Epiphany Biosciences - completed key Shingles & EBV proof-of.concept Phase 2 studies
Proven antiviral activity, dinical impact, & safety in multiple Phase
https://www.justice.gov/epstein/files/DataSet%209/EFTA00506070.pdf